Review of: "Synthesis of 1, 2-Disubstituted Benzimidazoles at Ambient Temperature Catalyzed by 1-Methylimidazolium Tetraflouroborate ([Hmim] BF_4) and Investigating Their Anti-ovarian Cancer Properties Through Molecular Docking Studies and Calculations"

Vishnu Thumma

Potential competing interests: No potential competing interests to declare.

1. The design rationale in the introduction is not proper. The manuscript work is focused on the synthesis of benzimidazole derivatives and their optimizations, but it is not mentioned anywhere about past work. It would be good if previous works were emphasized in the introduction part.
2. The author explained more about ovarian cancer rather than the role of benzimidazole scaffolds in cancer treatment. Please justify it.
3. In the molecular docking study, there is no Lee Pinsky's rule; moreover, it should be spelled as Lipinski's rule. Instead of "molecular docking," it should be mentioned as "prediction of drug-likeness properties."
4. Authors should explain ADME properties and molecular docking studies separately.
5. How did they validate the docking results? Not mentioned the docking scores of compounds anywhere?
6. Authors are requested to cite the following benzimidazole-based anticancer publications:

Chemistry Select, **2023**, 8(31), e202302393.

Molecular Diversity, **2023,** https://doi.org/10.1007/s11030-023-10661-3